Trial Profile
A Single-center, Open-label, Single-dose, Phase 1 Study to Evaluate the Pharmacokinetics (PK) of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment (HI).
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Oct 2018
Price :
$35
*
At a glance
- Drugs Daridorexant (Primary)
- Indications Insomnia
- Focus Pharmacokinetics
- 03 Oct 2018 New trial record